Magnitude of Viremia after Heart and Lung Transplantation from HCV Viremic Donors and Time to Clearance Based on Timing of Starting Therapy Post-Transplantation

Our study suggests that the magnitude and conversion to detectable viremia depends on the time of initiation of HCV therapy relative to time of transplant with complete conversion to HCV viremia in the HT group. Interestingly, there was no significance in time to viremia or HCV AB clearance between the two groups. This may be an organ specific response, but larger sample size studies need to be conducted to define the optimal time of starting HCV therapy.